Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
Trial details
- Registry ID
- NCT06359379
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as 5-iodo-2-pyrimidinone-2'-deoxyribose
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT PromoterNCT06359379 | Shuttle Pharmaceuticals, Inc. | Phase 2 | Terminated | 2025-12-01Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |